Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.67 and traded as high as $0.84. Xtant Medical shares last traded at $0.81, with a volume of 411,476 shares trading hands.

Analyst Ratings Changes

Separately, BTIG Research lowered their price objective on Xtant Medical from $2.00 to $1.50 and set a “buy” rating for the company in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Xtant Medical currently has an average rating of “Buy” and an average target price of $1.50.

Xtant Medical Trading Up 5.2%

The company has a quick ratio of 1.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.35. The company has a market cap of $113.40 million, a price-to-earnings ratio of 81.08 and a beta of -0.05. The firm has a 50 day moving average price of $0.72 and a two-hundred day moving average price of $0.67.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its earnings results on Monday, November 10th. The medical device company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The business had revenue of $27.77 million for the quarter, compared to analysts’ expectations of $32.70 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Hedge Funds Weigh In On Xtant Medical

A number of hedge funds have recently bought and sold shares of the company. Crescent Grove Advisors LLC boosted its position in Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after acquiring an additional 200,000 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Xtant Medical in the 2nd quarter valued at about $26,000. Nantahala Capital Management LLC boosted its position in shares of Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after purchasing an additional 57,000,000 shares in the last quarter. AWM Investment Company Inc. acquired a new stake in Xtant Medical during the second quarter worth approximately $4,875,000. Finally, Mink Brook Asset Management LLC increased its holdings in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares in the last quarter. Institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.